



Original article

Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource

Megan Druce^{1,2}, Chantal Hulo³, Patrick Masson³, Paula Sommer²,
Ioannis Xenarios³, Philippe Le Mercier³ and Tulio De Oliveira^{1,*}

¹Africa Centre for Population Health, School of Laboratory Medicine and Medical Sciences, Nelson R. Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa, ²Division of Genetics, School of Life Sciences, University of KwaZulu-Natal, Durban, South Africa, ³Swiss-Prot Group, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland

*Corresponding author: Tulio De Oliveira. Telephone: +27 31 260 5446, Fax: +27 31 35 550 7565, Email: tuliodna@gmail.com, tdeoliveira@afriacentre.ac.za

Citation details: Druce, M., Hulo, C., Masson, P. *et al.* Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource. Database (2016) Vol. 2016: article ID baw045; doi:10.1093/database/baw045

Received 9 November 2015; Revised 29 February 2016; Accepted 11 March 2016

Abstract

The Human Immunodeficiency Virus (HIV) is one of the pathogens that cause the greatest global concern, with approximately 35 million people currently infected with HIV. Extensive HIV research has been performed, generating a large amount of HIV and host genomic data. However, no effective vaccine that protects the host from HIV infection is available and HIV is still spreading at an alarming rate, despite effective antiretroviral (ARV) treatment. In order to develop effective therapies, we need to expand our knowledge of the interaction between HIV and host proteins. In contrast to virus proteins, which often rapidly evolve drug resistance mutations, the host proteins are essentially invariant within all humans. Thus, if we can identify the host proteins needed for virus replication, such as those involved in transporting viral proteins to the cell surface, we have a chance of interrupting viral replication. There is no proteome resource that summarizes this interaction, making research on this subject a difficult enterprise. In order to fill this gap in knowledge, we curated a resource presents detailed annotation on the interaction between the HIV proteome and host proteins. Our resource was produced in collaboration with ViralZone and used manual curation techniques developed by UniProtKB/Swiss-Prot. Our new website also used previous annotations of the BioAfrica HIV-1 Proteome Resource, which has been accessed by approximately 10 000 unique users a year since its inception in 2005. The novel features include a dedicated new page for each HIV protein, a graphic display of its function and a section on its interaction with host proteins. Our new webpages also add information on the genomic location of each HIV protein and the position of ARV drug resistance mutations. Our improved BioAfrica HIV-1 Proteome Resource fills a gap in the current knowledge of biocuration.

Database URL: <http://www.bioafrica.net/proteomics/HIVproteome.html>

Introduction

The objective of the BioAfrica HIV-1 Proteomics Resource is to provide accurate and comprehensive information on Human Immunodeficiency Virus (HIV) proteins. The first version of the resource was published in 2005 (1) and became popular across the scientific community. But, as with any resource, there is a need for information to be current and accurate. This is especially true in the fields of bioinformatics and proteomics, which have recently seen a massive increase in knowledge of both HIV-1 and host proteins as well on antiretroviral (ARV) drugs used for HIV treatment. In order to produce an accurate and comprehensive resource that complements other online protein resources, BioAfrica started to collaborate with Swiss-Prot ViralZone group of the Swiss Institute of Bioinformatics (SIB).

The collaboration of ViralZone and BioAfrica was funded by the Swiss South Africa Joint Research Programme (SSAJRP) in order to allow much of the knowledge produced by their independent projects to be synergized and presented in a new online section of the Swiss and South Africa academic websites. One of our main goals was to add information on ARV drug resistance and to generate new knowledge of the pathogen and host interaction. We also aimed to represent current understanding in an innovative and interactive way with graphical images and with links to relevant protein databases. We applied biocuration methods developed by UniProtKB/Swiss-Prot, which included manual extraction and structuring of information from the literature, manual verification of results from computational analyses, and mining and integration of large-scale datasets. The resource now includes protein structure and function, gene expression, post-transcriptional and translational modification, protease cleavage sites, drug resistance information and HIV and host protein interactions. In this biocuration paper, we present the upgrade of the BioAfrica HIV Proteome Resource and its synergetic interaction with ViralZone/SIB.

Methods

The original BioAfrica HIV-1 Proteome Resource and ViralZone were used as a starting point for the biocuration process. A team of researchers from South Africa and Switzerland updated the information using manual curation in accordance with Swiss-Prot standards (2). This involved reading a large number of abstracts, identifying relevant publications by searching literature databases and reviewing related UniProt protein pages. Papers were read in full and important information was extracted and summarized as text and images. We also manually accessed information in protein databases. Our updated resource

provides a webpage for each of the 22 HIV-1 proteins. Each webpage is divided into six sections. These are: (i) General Overview, (ii) Protein Function and Host–Virus Protein Interactions, (iii) Genomic Location and Protein Sequence, (iv) Protein Domains/Folds/Motifs, (v) HIV ARVs and Drug Resistance Mutations and (vi) Primary and Secondary Database Entries. All of the proteome pages end with a list of the referenced articles, which are linked to PubMed. Below we describe the methods used for each section.

(i) The General Overview contains information on the main function and localization of the protein in the HIV-1 replication cycle. This section describes: (a) the main function of the protein, (b) protein isoforms, (c) protein cleavage sites and when these exist, (d) localization of the protein within the virus and host cell and (e) additional information on protein function. The objective of this section is to allow users to access key information on the function of each HIV-1 protein as well as on key online resources. This was the last section to be curated as it summarizes information presented in the other sections of the webpage. It also provides key links to other online resources such as ViralZone (2) HIV replication cycle, the Protein Database (PDB), Uniprot and the GenBank.

(ii) The section on Protein Function and Host–Virus Protein Interactions was produced from a critical literature review of experimental and predicted host protein interaction for each HIV-1 protein. All interactions were manually verified for each protein sequence in UniProtKB. The interactions were summarized in graphical images that were created in Illustrator, following the standard process in ViralZone (2). One of the objectives was to create images that represented the function of the proteins and that used standard colours and shapes. Much of the work summarized in the images was produced by deep annotation made by the ViralZone group alone. The images are used on the ViralZone and BioAfrica websites. The dual display of this information allows synergy to be produced between the websites and information to be consistent across sites.

(iii) The Genomic Location and Protein Sequence section presents the genomic coordinates and amino acid sequence for each HIV-1 protein. The genomic location is presented as a graphical image and was produced by Rega Subtyping Tool Version 3.0 (3). The graphical image and numbering positioning are produced according to HIV-1 reference sequence (i.e. HXB2). The amino acid sequence of the protein is displayed and can be downloaded as FASTA sequence.

(iv) The Protein Domains/Folds/Motifs section contains information from the analysis of the amino acid sequences of the reference protein by InterPro (4) and Prosite (5).

InterPro is a freely available database that is used to classify sequences into protein families and to predict the presence of important domains and sites. The link provided to InterPro contains information on the biological process and molecular function of the main domain in the protein. For example, for HIV-1 protease, our resource links to the aspartic peptidase active site entry (IPR001969), which is a wide family of proteolytic enzymes known to exist in vertebrates, fungi, plants and retroviruses. The Prosite motifs of high probability of occurrence that are excluded from Interpro are also presented in the resource, such as *N*-glycosylation, *N*-myristoylation and protein kinase C phosphorylation site motifs.

(v) The HIV ARVs and Drug Resistance Mutations section is presented for the HIV-1 proteins that are targeted by ARVs. The section links information housed in ViralZone (2) and the Stanford HIV Drug Resistance Database (Stanford HIVDB) (6). The Stanford HIVDB contains detailed information on all of the licensed HIV drugs and how they interact with the HIV proteins (<http://hivdb.stanford.edu>). HIVDB also regularly provides an updated, in-depth, referenced summary of HIV drug resistance mutations. This is displayed in tables, with links to detailed information on how the mutations act on the HIV proteins in order to cause resistance. (http://bioafrica.mrc.ac.za/hivdb/pages/download/resistanceMutations_handout.pdf). This section contains a summary of the mechanism of action of the ARVs, which is followed by a table that highlights the drug resistance mutations and the ARVs affected. It was curated in collaboration with Stanford University HIV Drug Resistance Database (Stanford HIVdb) and links back to the respective pages on the Stanford HIVDB (6). We expect to continually upgrade the mutations and ARVs lists as we currently collaborate with Stanford on the maintenance of the southern African Stanford HIVDB mirror (7).

(vi) The Primary and Secondary Database Entries section provides links to related databases within each protein page of the HIV-1 Proteome Resource. All of the links are provided to the HIV-1 reference genome (HXB2). We have selected 15 well-curated databases to link to, including, among others, PDB/MMDB (<http://www.ncbi.nlm.nih.gov/structure>), Uniprot (<http://www.uniprot.org/>), EMBL-EBI (<http://www.ebi.ac.uk/Tools/dbfetch/>), InterPro (<http://www.ebi.ac.uk/interpro/>), Pfam (<http://pfam.xfam.org/>), SCOP (<http://supfam.org/SUPERFAMILY/index.html>), BLOCKS (<http://blocks.fhcrc.org/>), Prosite (<http://prosite.expasy.org/>), ProtoNet (<http://www.protonet.cs.huji.ac.il/index.php>), ModBase (<http://modbase.compbio.ucsf.edu/modbase-cgi/index.cgi>) and the HIV-1 Human Protein Interaction DB at NCBI (<http://www.ncbi.nlm.nih.gov/gene/155971>).

All of the proteome pages end with a list of the referenced articles, which are linked to PubMed. All of the links provided are functional and a script has been developed to check them every quarter. All of the updated webpages in the resource kept the original BioAfrica HIV proteomics resource html links. The reason for that is that these webpages also receive many links. For example, all of the 22 webpages of the resource are cross-linked from Uniprot in their HIV-1 reference sequence (i.e. HXB2) annotation page (e.g. <http://www.uniprot.org/uniprot/P04608>). The BioAfrica Proteome Resource is a part of <http://www.bioafrica.net> website. All pages from the previous version of the BioAfrica Proteome Resource are still online. However, we modified the html address to 'proteomics2005' (e.g. <http://www.bioafrica.net/proteomics2005/POL-PRprot.html>). This allows a comparison between the old and the newly upgraded resource (e.g. <http://www.bioafrica.net/proteomics/POL-PRprot.html>). In addition, [Supplementary Figure 1](#) shows the old and upgraded protease pages.

Results

Our results section starts by presenting information on the HIV-1 proteome (i.e. all HIV-1 proteins) and their interaction with host-proteins. Each protein is also described in detail in the six sections of the manuscript, which mimic the sections of our online resource. We use the Env gp120/gp41 and Rev annotation pages as examples to present some of the results of the biocuration process. Other proteins pages are available at <http://www.bioafrica.net/proteomics/HIVproteome.html>.


The HIV-1 genome is approximately 9.75 kb in length. It codes for only nine open reading frames (ORFs), including the Gag, Pol, Env, Tat, Rev, Nef, Vif, Vpr and Vpu genes. The HIV-1 genome is capable of producing 19 proteins via alternative splicing, alternative translation, ribosomal frameshift, alternative initiation and post-translational cleavages (8). Within the BioAfrica resource, there are 22 webpages dedicated to the 19 HIV-1 proteins and to the 3 polyproteins.

(i) General overview

Each HIV-1 protein page starts with a general overview. For example, the main function of the gp120 protein is viral attachment. This protein is an external membrane glycoprotein. It is localized at the host cell plasma membrane and virion envelope (more info at: <http://bioafrica.net/proteomics/ENV-GP120prot.html> and [Figure 1](#)). This section also contains a representative illustration of the protein in question. It also include a list of links to key online resources such as ViralZone, the Protein Database (PDB), Uniprot, the HIV-1/Human Protein Interaction

Gp120 - ENV Glycoprotein 120

HIV gp120 acts as a receptor on the surface of the viral particle, and binds to CD4 and secondary receptors on macrophages and T lymphocytes.



Isoforms:

- gp120 - exterior membrane glycoprotein (481 amino acids)

Function:

- Virion attachment and entry.
- Gp120 interacts with the **CD4 attachment receptor** and chemokine co-receptors, **CCR5** and **CXCR4**, for attachment and entry into the host cell.
- Gp120 is non-covalently bound to gp41, which transverses the lipid bilayer.

Localization:

- Cell plasma membrane
- Virion envelope

Additional Information:

- Late timing of expression.
- The **gp120-gp41** complex exists as a trimer on the surface of infected cells and the virion.
- Gp120 has 9 intrachain disulfide bonds.
- Gp120 has 5 hypervariable regions (V1 through V5).

Figure 1. The general overview section of the BioAfrica HIV-1 Proteome Resource, as shown by the gp120 protein.

Database, the Los Alamos HIV Sequence Database and EMBL/GenBank/DBJ links.

(ii) Protein function and host-virus protein interactions

This section includes a detailed and well-annotated image illustrating the function of the protein in question within the host cell and its host protein interactions. For example, on the Env gp120 proteome webpage (<http://bioafrica.net/proteomics/ENV-GP120prot.html> and Figure 2), the human proteins CD4, CCR5 and CXCR4, which are HIV-1 entry receptors found at the cell membrane are listed in the illustration and a link is provided to their Uniprot page. The gp120 webpage also links to a ViralZone webpage that describes in more detail the process of viral attachment to the host cell (http://viralzone.expasy.org/all_by_protein/3942.html). In addition, gp120 has been shown to interact with DC-SIGN/CD209 on the surface of dendritic cells to enhance virion transmission and infection. DC-SIGN also facilitates mucosal transmission by transporting HIV to lymphoid tissue (9,10).

Using the Rev protein page (<http://bioafrica.net/proteomics/REVprot.html>) as a second example, we show the Rev-mediated export of unspliced or incompletely spliced viral RNA transcripts from the host nucleus to the cytoplasm, facilitated by various Rev-host protein interactions

(11–13). Host-virus protein interactions highlighted in the image at the webpage, include CRM1/XPO1, Importin-beta 1, B23, DDX3X and Sam68. Importin-beta 1 (14) and B23 (15) form a complex with RanGTP and Rev to facilitate the transport of Rev from the host cell cytoplasm to the nucleus. Once inside the host nucleus, DDX1 binds to Rev and the Rev-responsive element (RRE) to facilitate their transport within the cell nucleus (16). Following this CRM1, the Rev-RRE nuclear export receptor is bound by RanGTP to form a CRM1-RanGTP complex. This induces the formation of a Rev-RRE-CRM1-RanGTP complex and initiates the export of Rev-RRE out of the nucleus (17). DDX3 (18) and Sam68 (19) bind to this complex and enhance the Rev-mediated nuclear export of viral RNA. Further host-Rev protein interactions not highlighted in the image include DDX5 and DDX24. It has been proposed that the Rev-DDX5 interaction plays a role in HIV-1 replication and association interference could result in the reduction of viral replication (20).

In addition, all host and virus proteins have been linked to their appropriate UniProt (<http://www.uniprot.org/>) pages. Together, the Protein Function and Host-Virus Protein Interactions section provides users with an illustrated description of the role of the HIV-1 protein within the virus life cycle as well as descriptions of host-virus protein interactions linked to relevant publications and resources. All interactions listed have been proved by dozens




Figure 2. HIV-1 Gp120 and Gp41 protein interaction with human proteins CD4 and CCR5, as shown by the Env protein attachment, co-receptor binding and fusion image.

of experiments, which were manually curated from the literature. Table 1 summarizes information on the host protein interactions for all HIV-1 proteins.

(iii) Genomic location and protein sequence

This section provides a graphical representation of the location of the HIV-1 protein sequence in question relative to the HIV-1_{HXB2} reference genome (96). This is followed by the amino acid sequence data (FASTA format). For example, the gp120 is a protein that contains 481 amino acids with a molecular weight of 53 922 Da and theoretical PI of 9.05 (Figure 3). This protein is formed after a 30 amino acid signal peptide is cleaved from the amino terminal part of the ENV protein.

(iv) Protein domains/folds/motifs

As in the original version of the BioAfrica HIV-1 Proteomics Resource, the section on protein domains/folds/motifs includes information about the predicted motifs and structure of the protein as well as the protein functional domains (1). For example, the gp120 had five variable loops (V1–V5). The V3 loop interacts with CXCR4 and CCR5 chemokine receptors and it is

important for determining the preferential tropism for either T lymphocytes or primary macrophages (Figure 4). This section also includes information relating to protein secondary structure, low complexity regions, myristoylation, phosphorylation and glycosylation. For example, we list the Highly conserved intrachain disulfide bonds at cysteine (Cys) Cys54–Cys74, Cys119–Cys205, Cys126–Cys196, etc. (<http://bioafrica.net/proteomics/ENV-GP120prot.html>).

(V) HIV ARVs and drug resistance mutations

The ARVs and Drug Resistance Mutations section is a new development to the BioAfrica Proteomics Resource. The section includes all ARVs targeting an HIV protein. These include protease (www.bioafrica.net/proteomics/POL-PRprot.html), reverse transcriptase (<http://www.bioafrica.net/proteomics/POL-RTprot.html>), integrase (<http://www.bioafrica.net/proteomics/POL-INprot.html>) and envelope gp120/gp41 proteins (<http://www.bioafrica.net/proteomics/ENVprot.html>). For each of these protein pages, there is an additional section that provides users with an overview of the current ARVs. Information in this section also includes descriptions of the type and position of the mutation and relevant publications. Using Env as an

Table 1. Summarizes information on the main function of the proteins, their location on the host cell and host-virus protein interactions

HIV protein	Main function	Location	Host protein interaction	References
Env	Precursor of gp120 and gp41	ER and Golgi		
Gp120	Virion attachment	Cell plasma membrane and virion envelope	CD4, CCR5, CXCR4, DC-SIGN/CD209	(21–24)
Gp41	Mediates the fusion of viral and cellular membranes	Cell plasma membrane and virion envelope		
Gag	Mediates essential virion assembly and budding events	Cell plasma membrane, virion, host cytoplasm and late endosome/multivesicular bodies	ESCRT system, various interactions specific to each Gag protein product	(25)
P17 (Matrix)	Mediates virion assembly by targeting Gag and polyproteins to the plasma membrane and incorporates Env into budding virions	Inner surface of virion lipid bilayer, host cell cytoplasm, cell nucleus, late endosomes/multivesicular bodies and plasma membrane	Calmodulin (CaM), AP-2 and AP-3	(26–28)
P24 (Capsid)	Forms a cone-shaped shell that encapsulates the RNA-nucleocapsid complex and mediates its delivery into the host nucleus	Virion and host cell cytoplasm	Cyclophilin A, NUP358, NUP153, CPSF6, PIN1, TRIM5alpha, NUP98	(29–34)
P2 (Spacer Peptide 1)	Spacer peptide	Virion and host cell cytoplasm	No known interactions	
P7 (Nucleocapsid)	Encapsulates and protects viral genomic RNA and enhances various steps in virion reverse transcription	Virion, host cell cytoplasm and host nucleus	Alix, STAU1, ABCE1, EAP30, ESCRT-II, DHX9	(35–39)
P1 (Spacer Peptide 2)	Spacer peptide	Virion	No known interactions	
P6	Facilitates ESCRT-dependent virus budding and mediates Vpr incorporation into virions	Virion and host cell cytoplasm	ESCRT, Tsg101, Alix	(25,40,41)
Nef	Mediates MHC-I and CD4 down-regulation and prevents apoptosis	Cell plasma membrane and host cell cytoplasm	CD4, AP1M1, AP2M1, MHC-I, ASK1, Alix, ACOT8, PACS-1, PACS-2, PAK2, LCK, HCK, ABCA1, Calnexin, Catenin beta-1	(42–56)
Gag-Pol	Mediates essential virion assembly and the release of protease from Pol triggers virion maturation	Virion, host cell cytoplasm, cell plasma membrane and late endosomes/multivesicular bodies	Interaction experiments performed for Gag	
P15 (Protease)	Initiates virion maturation	Virion and host cell cytoplasm	N/A	
P51 (Reverse Transcriptase)	Converts viral ssRNA into dsDNA for its subsequent integration into the host genome	Virion, host cell cytoplasm and nucleus	N/A	
P15 (RNase H)	Removes the RNA template strand from the RNA/DNA duplex	Virion	N/A	
P31 (Integrase)	Catalyzes viral DNA integration into the host genome	Virion, host cell nucleus and cytoplasm	LEDGF/p75, INI1/SMARCB1, Importin alpha 3, Importin 7, UNG, Transportin-3, NUP153, NUP62, Gemin2	(57–65)
P19 (Rev)	Binds to the <i>Rev Response Element</i> (RRE) to facilitate the nuclear export of unspliced or incompletely spliced viral RNAs to the cytoplasm	Host cell nucleus/nucleolus and cytoplasm	CRM1/XPO1, Importin-beta1, B23, DDX3X, Sam68, DDX1, DDX5, DDX24	(14–20,66)

(continued)

Table 1. Continued

HIV protein	Main function	Location	Host protein interaction	References
Tat (P14/P16)	Binds to the <i>transactivating responsive sequence</i> (TAR) RNA element to recruit certain host proteins and promote HIV-1 transcription	Host cell nucleus/nucleolus, extra-cellular regions and host cytoplasm	Cyclin T1, CDK9, P300, CBP, Sp1, DDX3X, NAPIL1, INI1/SMARCB1, MED14, TIP110, SMARCA4, Importin beta 1, NFAT1	(67–77)
P23 (Vif)	Counteracts the innate antiviral activity of host cytidine deaminase nucleic editing enzymes	Virion, host cell cytoplasm and membrane	APOBEC3G, APOBEC3F, APOBEC3D, APOBEC3H, ELOB, ELOC, CUL5, RBX1, CBF-beta	(78–85)
Vpr (p10/p12)	Plays a role in the nuclear entry of the viral cDNA genome and degrades host Uracil-DNA glycosylase. Also induces host cell G2 arrest	Virion and host cell nucleus	UNG, VPRBP/DCAF1, Importin alpha 1, RAD23A	(86–89)
P16 (Vpu)	Induces the down-regulation of CD4 and promotes progeny virion release by antagonizing host tetherin/BST2	Virion, host cell cytoplasm and membrane	CD4, β TrCp, NTB-A, CD155, tetherin/BST2, AP1M1	(90–95)




Figure 3. The genomic location and protein sequence section of the BioAfrica Proteome Resource Env gp120 protein.

Protein Domains/Folds/Motifs: [TOP]

InterPro signature for Envelope glycoprotein GP120 - IPR000777

Hypervariable regions (V1 through V5):

V1 variable loop:

V2 variable loop:

V3 variable loop:

- Is not involved in CD4 binding, but is important for determining the preferential tropism for either T lymphocytes or primary macrophages
- Interacts with CXCR4 and CCR5 chemokine receptors
- Is the primary target for neutralizing antibodies that block HIV-1 infectivity

V4 variable loop:

V5 variable loop:

Highly conserved intrachain disulfide bonds:

(Cys54 - Cys74)
 (Cys119 - Cys205)
 (Cys126 - Cys196)
 (Cys131 - Cys157)
 (Cys218 - Cys247)
 (Cys228 - Cys239)
 (Cys296 - Cys331)
 (Cys378 - Cys445)
 (Cys385 - Cys418)

Secondary Structure Prediction:

Antigenic Sites - EMBOSS:

Predicted Motifs: Printer-friendly version

N-glycosylation: 24 potential sites

N-myristoylation: 8 potential sites

Amidation: none

Protein kinase C: 8 potential sites

Casein kinase II: 5 potential sites

Tyrosine kinase: none

cAMP / cGMP kinase: none

Cell attachment motif: none

Asp Protease motif: none

Asp Prot Retro motif: none

Cysteine-rich Region: none

Tryptophan-rich Region: none

Zinc-finger CCHC motif: none

Leucine Zipper motif: none

Figure 4. The protein domains/folds/motifs section of the BioAfrica HIV-1 Proteome Resource, exemplified by the gp120.

example, there is only one fusion inhibitor that has been approved for HIV treatment, namely Enfuvirtide. This 36 amino acid polypeptide binds to the heptad repeat (HR) regions of the gp41 viral protein and engages in a coil-coil interaction. This interaction inhibits the fusion of viral and cellular membranes and thus prevents the entry and infection of HIV. There are six drug resistance mutations (positions 36–38, 40, 42–43) that have been well described in the literature (97) (Table 2). A further two potential mutations have been identified but need to be tested phenotypically. In addition to Env, there are ARVs and drug resistance sections on the reverse transcriptase, protease and integrase webpages. For example, the K103R mutation on the reverse transcriptase affects the ARVs Nevirapine (NVP), Delavirdine (DLV) and Efavirenz (EFV) and reduces the virus susceptibility to these drugs (7,13). Furthermore, when in combination with the V179D mutation, K103R mutants can decrease HIV susceptibility to NVP, DLV and EFV by 15-fold (99). All drug resistance mutations are based on the HIV-1 subtype B reference sequence (HXB2), however, we also link from the resource recent reviews that add information related to drug

resistance to HIV-1 subtype C, which is the most prevalent HIV-1 strain in the world.

(vi) Primary and secondary database entries

The primary and secondary database entries section lists links to relevant online resources containing information about different aspects of the virus protein (Figure 5). Options include specific databases that provide users with sequence, function and protein-protein interaction data for each HIV-1 protein, as well as protein family annotations and post-translational modification information. A graphical representation (PDB format) of the protein is also provided in this section with links to the protein data bank entry. All of the proteome pages end with a list of the referenced articles, which are linked to PubMed. For example, for gp120 we provide 19 key references that were used in the curation process. The citations normally start with a link to the Los Alamos HIV Database Compendium and to the Retroviruses book, which are online accessible resources that contain detailed information about each protein. This is followed by the original publication on the

Table 2. The HIV ARVs and drug resistance mutations section of the BioAfrica HIV-1 Proteome Resource, shown by the Env poly-protein page (<http://bioafrica.net/proteomics/ENVprot.html>)

Protein position	Mutation	Additional information	Drugs affected	Reference
G36	D, E, V, S	G36D/E mutations are associated with a large decrease in Enfuvirtide susceptibility (>10-fold)	Enfuvirtide	(97)
I37	V		Enfuvirtide	(97)
V38	E, A, M, G	V38E/A mutations are associated with a large decrease in Enfuvirtide susceptibility (>10-fold)	Enfuvirtide	(97)
Q40	H	Mutation is associated with a large decrease in Enfuvirtide susceptibility (>10-fold)	Enfuvirtide	(97)
N42	T, S	N42S occurs in ~15% of viruses from Enfuvirtide-naive patients and does not decrease drug susceptibility	Enfuvirtide	(97,98)
N43	D, K, S	N43D mutation is associated with a large decrease in Enfuvirtide susceptibility (>10-fold)	Enfuvirtide	(97)
L44	M		Enfuvirtide	(97)
L45	M		Enfuvirtide	(97)

Primary and Secondary Database Entries: [\[TOP\]](#)


Identifiers:	PDB:
<p>ViralZone: HIV-1, HIV replication cycle, HIV resource PDB/MMDB: Search for HIV-1 & Capsid UniProt: P04591 (HIV-1 HXB2 GAG) EMBL: K03455; AAB50258.1 [EMBL/GenBank/DBJ] InterPro: IPR008916 - Retroviral Core Antigen C-terminal Domain / IPR008919 - Retroviral Core Antigen N-terminal Core Domain Pfam: PF00607 Prints: none SCOP: SSF47943 Retroviral Core Antigen N-terminus / SSF47353 Retroviral Core Antigen N-terminus BLOCKS: P04591 Prosite: P04591 ProtoNet: P04591 Database of Interacting Proteins: P04591 ModBase: P04591 HIV-1/Human Protein Interaction DB: HIV-1 Gag HIV-1 Sequence Database Los Alamos HIV Sequence Database</p>	<p>PDB:</p> 

Figure 5. The primary and secondary database entries section of the BioAfrica HIV-1 Proteome Resource, seen on the Gag capsid protein.

function of each protein, which in the case of the envelope, is a Nature publication from 1988 that describes how a glycoprotein of HIV-1 binds to the immunoglobulin-like domain of CD4 (100).

Discussion

Upgrading BioAfrica in collaboration with ViralZone and with the use of SwissProt curation methods was a time consuming but worthwhile undertaking. The process consisted of reading hundreds of manuscripts to critically review experimental and predicted data for each HIV protein as well as host proteins that interact with HIV. Curation included extracting and structuring information from the literature, manually verifying results from computational analyses

and mining large-scale protein datasets. The process involved collaboration with professional curators from Switzerland and the training of South African researchers in biocuration. Furthermore, it provided synergy between BioAfrica and ViralZone information, which will allow users to access high-quality information that is available in two popular protein curation resources.

Prior to the upgrade of BioAfrica, the majority of resources only provided users with information about the virus or the host proteins. In addition, no resource linked this information to ARVs and drug resistance mutations. Our online resource provides comprehensive detail about various aspects of each HIV-1 gene product. It now includes information about protein isoforms, localization, function, sequence data (based on the HIV-1 reference

sequence HXB2), protein domains/folds/motifs and host and virus protein-protein interactions. We believe that the easy access to well curated and current information will advance HIV drug resistance and HIV vaccine research and will provide a better understanding of the interaction between the host and the virus.

Supplementary data

Supplementary data are available at *Database Online*.

Funding

the Swiss South African Joint Research Programme (SSJRP) research grant entitled "Swiss Prot / South Africa: Protein Bioinformatics Resource Development for Important Health-related Pathogens. The Swiss Federal Government through the State Secretariat for Education, Research and Innovation. Flagship grant from the Medical Research Council (MRC) of the Republic of South Africa (MRC-RFA-UFSP-01-2013/UKZN HIVEPI) the Wellcome Trust (082384/Z/07/Z) a Royal Society Newton Advanced Fellowship (T de Oliveira).

Conflict of interest. None declared.

References

- Doherty,R.S., De Oliveira,T., Seebregts,C. *et al.* (2005) BioAfrica's HIV-1 proteomics resource: combining protein data with bioinformatics tools. *Retrovirology*, 2, 18.
- Hulo,C., de Castro,E., Masson,P. *et al.* (2011) ViralZone: a knowledge resource to understand virus diversity. *Nucleic Acids Res.*, 39, D576–D582.
- De Oliveira,T., Deforche,K., Cassol,S. *et al.* (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. *Bioinf. Oxf. Engl*, 21, 3797–3800.
- Mitchell,A., Chang,H., Daugherty,L. *et al.* (2015) The InterPro protein families database: the classification resource after 15 years. *Nucleic Acids Res.*, 43, D213–D221.
- Sigrist,C.J.A., de Castro,E., Cerutti,L. *et al.* (2013) New and continuing developments at PROSITE. *Nucleic Acids Res.*, 41, D344–D347.
- Shafer,R.W. (2006) Rationale and uses of a public HIV drug-resistance database. *J. Infect. Dis.*, 194, S51–S58.
- De Oliveira,T., Shafer,R.W. and Seebregts,C. (2010) Public database for HIV drug resistance in southern Africa. *Nature*, 464, 673.
- Freed,E.O. (2001) HIV-1 replication. *Somat. Cell Mol. Genet.*, 26, 13–33.
- Deng,H., Liu,R., Ellmeier,W. *et al.* (1996) Identification of a major co-receptor for primary isolates of HIV-1. *Nature*, 381, 661–666.
- Curtis,B.M., Scharnowske,S. and Watson,A.J. (1992) Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. *Proc. Natl. Acad. Sci. U. S. A.*, 89, 8356–8360.
- Hope,T.J. (1999) The ins and outs of HIV Rev. *Arch. Biochem. Biophys.*, 365, 186–191.
- Kim,S.Y., Byrn,R., Groopman,J. *et al.* (1989) Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. *J. Virol.*, 63, 3708–3713.
- Kuzembayeva,M., Dilley,K., Sardo,L. *et al.* (2014) Life of psi: how full-length HIV-1 RNAs become packaged genomes in the viral particles. *Virology*, 454–455, 362–370.
- Henderson,B.R. and Percipalle,P. (1997) Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. *J. Mol. Biol.*, 274, 693–707.
- Fankhauser,C., Izaurralde,E., Adachi,Y. *et al.* (1991) Specific complex of human immunodeficiency virus type 1 rev and nucleolar B23 proteins: dissociation by the Rev response element. *Mol. Cell. Biol.*, 11, 2567–2575.
- Fang,J., Kubota,S., Yang,B. *et al.* (2004) A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. *Virology*, 330, 471–480.
- Askjaer,P., Jensen,T.H., Nilsson,J. *et al.* (1998) The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. *J. Biol. Chem.*, 273, 33414–33422.
- Yasuda-Inoue,M., Kuroki,M. and Ariumi,Y. (2013) Distinct DDX DEAD-box RNA helicases cooperate to modulate the HIV-1 Rev function. *Biochem. Biophys. Res. Commun.*, 434, 803–808.
- Modem,S., Badri,K.R., Holland,T.C. *et al.* (2005) Sam68 is absolutely required for Rev function and HIV-1 production. *Nucleic Acids Res.*, 33, 873–879.
- Zhou,X., Luo,J., Mills,L. *et al.* (2013) DDX5 facilitates HIV-1 replication as a cellular co-factor of Rev. *PLoS One*, 8, e65040.
- McDougal,J.S., Kennedy,M.S., Slish,J.M. *et al.* (1986) Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. *Science*, 231, 382–385.
- Wu,L., Gerard,N.P., Wyatt,R. *et al.* (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. *Nature*, 384, 179–183.
- Bandres,J.C., Wang,Q.F., O'Leary,J. *et al.* (1998) Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. *J. Biol. Chem.*, 273, 2500–2504.
- Geijtenbeek,T.B., Kwon,D.S., Torensma,R. *et al.* (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. *Cell*, 100, 587–597.
- Meng,B. and Lever,A.M. (2013) Wrapping up the bad news: HIV assembly and release. *Retrovirology*, 10, 5.
- Vlach,J., Samal,A.B. and Saad,J.S. (2014) Solution structure of calmodulin bound to the binding domain of the HIV-1 matrix protein. *J. Biol. Chem.*, 289, 8697–8705.
- Batonick,M., Favre,M., Boge,M. *et al.* (2005) Interaction of HIV-1 Gag with the clathrin-associated adaptor AP-2. *Virology*, 342, 190–200.
- Dong,X., Li,H., Derdowski,A. *et al.* (2005) AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. *Cell*, 120, 663–674.
- Gamble,T.R., Vajdos,F.F., Yoo,S. *et al.* (1996) Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. *Cell*, 87, 1285–1294.
- Schaller,T., Ocwieja,K.E., Rasaiyaah,J. *et al.* (2011) HIV-1 capsid-cyclophilin interactions determine nuclear import pathway,

- integration targeting and replication efficiency. *PLoS Pathog.*, 7, e1002439.
31. Di Nunzio,F., Fricke,T., Miccio,A. *et al.* (2013) Nup153 and Nup98 bind the HIV-1 core and contribute to the early steps of HIV-1 replication. *Virology*, 440, 8–18.
 32. Price,A.J., Fletcher,A.J., Schaller,T. *et al.* (2012) CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. *PLoS Pathog.*, 8, e1002896.
 33. Misumi,S., Inoue,M., Dochi,T. *et al.* (2010) Uncoating of human immunodeficiency virus type 1 requires prolyl isomerase Pin1. *J. Biol. Chem.*, 285, 25185–25195.
 34. Stremlau,M., Perron,M., Lee,M. *et al.* (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5 β Restriction factor. *Proc. Natl. Acad. Sci. U. S. A.*, 103, 5514–5519.
 35. Dussupt,V., Javid,M.P., Abou-Jaoude,G. *et al.* (2009) The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding. *PLoS Pathog.*, 5, e1000339.
 36. Chatel-Chaix,L., Boulay,K., Moulant,A.J. *et al.* (2008) The host protein Staufen1 interacts with the Pr55Gag zinc fingers and regulates HIV-1 assembly via its N-terminus. *Retrovirology*, 5, 41.
 37. Lingappa,J.R., Dooher,J.E., Newman,M.A. *et al.* (2006) Basic residues in the nucleocapsid domain of Gag are required for interaction of HIV-1 gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly. *J. Biol. Chem.*, 281, 3773.
 38. Ghoujal,B., Milev,M.P., Ajamian,L. *et al.* (2012) ESCRT-II's involvement in HIV-1 genomic RNA trafficking and assembly. *Biol. Cell Auspices Eur. Cell Biol. Organ.*, 104, 706–721.
 39. Roy,B.B., Hu,J., Guo,X. *et al.* (2006) Association of RNA helicase a with human immunodeficiency virus type 1 particles. *J. Biol. Chem.*, 281, 12625–12635.
 40. Garrus,J.E., von Schwedler,U.K., Pornillos,O.W. *et al.* (2001) Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. *Cell*, 107, 55–65.
 41. Strack,B., Calistri,A., Craig,S. *et al.* (2003) AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. *Cell*, 114, 689–699.
 42. Preusser,A., Briese,L., Baur,A.S. *et al.* (2001) Direct in vitro binding of full-length human immunodeficiency virus type 1 Nef protein to CD4 cytoplasmic domain. *J. Virol.*, 75, 3960–3964.
 43. Noviello,C.M., Benichou,S. and Guatelli,J.C. (2008) Cooperative binding of the class I major histocompatibility complex cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu subunit. *J. Virol.*, 82, 1249–1258.
 44. Jin,Y.J., Cai,C.Y., Mezei,M. *et al.* (2013) Identification of a novel binding site between HIV type 1 Nef C-terminal flexible loop and AP2 required for Nef-mediated CD4 downregulation. *AIDS Res. Hum. Retroviruses*, 29, 725–731.
 45. Williams,M., Roeth,J.F., Kasper,M.R. *et al.* (2002) Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. *J. Virol.*, 76, 12173–12184.
 46. Xu,X.N. and Screaton,G. (2001) HIV-1 Nef: negative effector of Fas? *Nat. Immunol.*, 2, 384–385.
 47. Amorim,N.A., da Silva,E.M.L., de Castro,R.O. *et al.* (2014) Interaction of HIV-1 Nef Protein with the Host Protein Alix Promotes Lysosomal Targeting of CD4 Receptor. *J. Biol. Chem.*, 289, 27744–27756.
 48. Watanabe,H., Shiratori,T., Shoji,H. *et al.* (1997) A novel acyl-CoA thioesterase enhances its enzymatic activity by direct binding with HIV Nef. *Biochem. Biophys. Res. Commun.*, 238, 234–239.
 49. Dikeakos,J.D., Thomas,L., Kwon,G. *et al.* (2012) An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I. *Mol. Biol. Cell.*, 23, 2184–2197.
 50. Atkins,K.M., Thomas,L., Youker,R.T. *et al.* (2008) HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation: analysis using short interfering RNA and knock-out mice. *J. Biol. Chem.*, 283, 11772–11784.
 51. Agopian,K., Wei,B.L., Garcia,J.V. *et al.* (2006) A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2. *J. Virol.*, 80, 3050–3061.
 52. Dutartre,H., Harris,M., Olive,D. *et al.* (1998) The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phosphotyrosine independent mechanism. *Virology*, 247, 200–211.
 53. Briggs,S.D., Sharkey,M., Stevenson,M. *et al.* (1997) SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1. *J. Biol. Chem.*, 272, 17899–17902.
 54. Mujawar,Z., Tamehiro,N., Grant,A. *et al.* (2010) Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation. *Biochemistry (Mosc.)*, 49, 8338–8349.
 55. Jennelle,L., Hunegnaw,R., Dubrovsky,L. *et al.* (2014) HIV-1 protein Nef inhibits activity of ATP-binding cassette transporter A1 by targeting endoplasmic reticulum chaperone calnexin. *J. Biol. Chem.*, 289, 28870–28884.
 56. Weiser,K., Barton,M., Gershoony,D. *et al.* (2013) HIV's Nef interacts with β -catenin of the Wnt signaling pathway in HEK293 cells. *PLoS One*, 8, e77865.
 57. Engelman,A. and Cherepanov,P. (2008) The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. *PLoS Pathog.*, 4, e1000046.
 58. Kalpana,G.V., Marmon,S., Wang,W. *et al.* (1994) Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. *Science*, 266, 2002–2006.
 59. Ao,Z., Danappa Jayappa,K., Wang,B. *et al.* (2010) Importin alpha3 interacts with HIV-1 integrase and contributes to HIV-1 nuclear import and replication. *J. Virol.*, 84, 8650–8663.
 60. Ao,Z., Huang,G., Yao,H. *et al.* (2007) Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. *J. Biol. Chem.*, 282, 13456–13467.
 61. Priet,S., Navarro,J.M., Gros,N. *et al.* (2003) Functional role of HIV-1 virion-associated uracil DNA glycosylase 2 in the correction of G:U mispairs to G:C pairs. *J. Biol. Chem.*, 278, 4566–4571.
 62. Larue,R., Gupta,K., Wuensch,C. *et al.* (2012) Interaction of the HIV-1 intasome with transportin 3 protein (TNPO3 or TRN-SR2). *J. Biol. Chem.*, 287, 34044–34058.

63. Woodward,C.L., Prakobwanakit,S., Mosessian,S. *et al.* (2009) Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1. *J. Virol.*, 83, 6522–6533.
64. Ao,Z., Jayappa,K.D., Wang,B. *et al.* (2012) Contribution of host nucleoporin 62 in HIV-1 integrase chromatin association and viral DNA integration. *J. Biol. Chem.*, 287, 10544–10555.
65. Nishitsuji,H., Hayashi,T., Takahashi,T. *et al.* (2009) Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 Is critical for HIV-1 infection. *PLoS One*, 4, e7825.
66. Ma,J., Rong,L., Zhou,Y. *et al.* (2008) The requirement of the DEAD-box protein DDX24 for the packaging of human immunodeficiency virus type 1 RNA. *Virology*, 375, 253–264.
67. Wei,P., Garber,M.E., Fang,S.M. *et al.* (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell*, 92, 451–462.
68. Marzio,G., Tyagi,M., Gutierrez,M.I. *et al.* (1998) HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. *Proc. Natl. Acad. Sci. U. S. A.*, 95, 13519–13524.
69. Jeang,K.T., Chun,R., Lin,N.H. *et al.* (1993) In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. *J. Virol.*, 67, 6224–6233.
70. Lai,M.C., Wang,S.W., Cheng,L. *et al.* (2013) Human DDX3 interacts with the HIV-1 Tat protein to facilitate viral mRNA translation. *PLoS One*, 8, e68665.
71. Vardabasso,C., Manganaro,L., Lusic,M. *et al.* (2008) The histone chaperone protein Nucleosome Assembly Protein-1 (hNAP-1) binds HIV-1 Tat and promotes viral transcription. *Retrovirology*, 5, 8.
72. Mahmoudi,T., Parra,M., Vries,R.G.J. *et al.* (2006) The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. *J. Biol. Chem.*, 281, 19960–19968.
73. Ruiz,A., Pauls,E., Badia,R. *et al.* (2014) Characterization of the influence of mediator complex in HIV-1 transcription. *J. Biol. Chem.*, 289, 27665–27676.
74. Liu,Y., Li,J., Kim,B.O. *et al.* (2002) HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110. *J. Biol. Chem.*, 277, 23854–23863.
75. Agbottah,E., Deng,L., Dannenberg,L.O. *et al.* (2006) Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. *Retrovirology*, 3, 48.
76. Truant,R. and Cullen,B.R. (1999) The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. *Mol. Cell. Biol.*, 19, 1210–1217.
77. Macián,F. and Rao,A. (1999) Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1. *Mol. Cell. Biol.*, 19, 3645–3653.
78. Marin,M., Rose,K.M., Kozak,S.L. *et al.* (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. *Nat. Med.*, 9, 1398–1403.
79. Wiegand,H.L., Doehle,B.P., Bogerd,H.P. *et al.* (2004) A Second Human Antiretroviral Factor, Apobec3f, Is Suppressed by the Hiv-1 and Hiv-2 Vif Proteins. *Embo J.*, 23, 2451–2458.
80. Feng,Y., Baig,T.T., Love,R.P. *et al.* (2014) Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. *Front. Microbiol.*, 5, 450.
81. Bergeron,J.R.C., Huthoff,H., Veselkov,D.A. *et al.* (2010) The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. *PLoS Pathog.*, 6, e1000925.
82. Da Costa,K.S., Leal,E., dos Santos,A.M. *et al.* (2014) Structural analysis of viral infectivity factor of HIV type 1 and its interaction with A3G, EloC and EloB. *PLoS One*, 9, e89116.
83. Evans,S.L., Sch—n,A., Gao,Q. *et al.* (2014) HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. *Retrovirology*, 11, 4.
84. Yu,X., Yu,Y., Liu,B. *et al.* (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. *Science*, 302, 1056–1060.
85. Matsui,Y., Shindo,K., Nagata,K. *et al.* (2014) Defining HIV-1 Vif residues that interact with CBF β by site-directed mutagenesis. *Virology*, 449, 82–87.
86. Bouhamdan,M., Benichou,S., Rey,F. *et al.* (1996) Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. *J. Virol.*, 70, 697–704.
87. Transy,C. and Margottin-Goguet,F. (2009) HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. *Cell Cycle Georget. Tex.*, 8, 2489–2490.
88. Kamata,M., Nitahara-Kasahara,Y., Miyamoto,Y. *et al.* (2005) Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr. *J. Virol.*, 79, 3557–3564.
89. Withers-Ward,E.S., Jowett,J.B., Stewart,S.A. *et al.* (1997) Human immunodeficiency virus type 1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. *J. Virol.*, 71, 9732–9742.
90. Singh,S.K., Möckel,L., Thiagarajan-Rosenkranz,P. *et al.* (2012) Mapping the Interaction between the Cytoplasmic Domains of HIV-1 Viral Protein U And Human Cd4 with Nmr Spectroscopy. *FEBS J.*, 279, 3705–3714.
91. Margottin,F., Bour,S.P., Durand,H. *et al.* (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. *Mol. Cell.*, 1, 565–574.
92. Bolduan,S., Hubel,P., Reif,T. *et al.* (2013) HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A. *Virology*, 440, 190–203.
93. Bolduan,S., Reif,T., Schindler,M. *et al.* (2014) HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain. *Virology*, 464–465, 375–384.
94. Skasko,M., Wang,Y., Tian,Y. *et al.* (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. *J. Biol. Chem.*, 287, 58–67.
95. Jia,X., Weber,E., Tokarev,A. *et al.* (2014) Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. *eLife*, 3, e02362.
96. Ratner,L., Haseltine,W., Patarca,R. *et al.* (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. *Nature*, 313, 284.

97. Bennett,D.E., Camacho,R.J., Otelea,D. *et al.* (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. *PloS One*, 4, e4724.
98. Melby,T., Sista,P., DeMasi,R. *et al.* (2006) Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. *AIDS Res. Hum. Retroviruses*, 22, 375–385.
99. Parkin,N.T., Gupta,S., Chappey,C. *et al.* (2006) The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. *Antimicrob. Agents Chemother.*, 50, 351–354.
100. Landau,N.R., Warton,M. and Littman,D.R. (1988) The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. *Nature*, 334, 159–162.